Innoviva (INVA) Stock Forecast & Price Target

Innoviva is favored because its durable Breo and Anoro royalty stream provides highly visible capital through 2030, with roughly $1.0B in expected royalty revenue over the next five years, while its 1Q26 results also showed $603.1M in cash and strong investment gains. Its operating IST platform is gaining momentum, as 2Q26 U.S. product revenue grew 26% year over year to $36.6M and internally marketed products exceeded $180M in LTM revenue as of March 2026, led by Giapreza and XacDuro. The outlook is further strengthened by capital-efficient pipeline expansion through Nortiva Bio’s LYNX platform, a healthy deal pipeline, and strategic stakes such as Armata, while share repurchases add an additional shareholder-friendly lever.

Innoviva is facing a weaker royalty stream, with quarterly royalty revenue of $59.8M, down 11% year over year, as GSK cited U.S. pricing pressure and softer inhaled respiratory demand, while FactSet consensus for 2026/2027 has fallen about 6%-7%. The company also faces product and clinical execution risk, since Zevtera sales are only about $0.4M and expectations were cut materially from a prior peak of roughly $72M to $39M in 2033E, while the potential zoliflodacin launch in early 2026 could still underperform. On top of that, Innoviva’s valuation is sensitive to its Armata stake, and a ~28% decline in 3Q26 implies up to a $65M negative fair value adjustment QTD, highlighting capital allocation and portfolio-concentration risk.